GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
SUCAMPO PHARMACEUTICALS INC (SCMP) [hlAlert]

Rating:
Buy SCMP
up 316.71 %

SUCAMPO PHARMACEUTICALS INC (SCMP) rated Buy with price target $10 by Cantor Fitzgerald

Posted on: Tuesday,  Apr 23, 2013  2:25 PM ET by Cantor Fitzgerald

Cantor Fitzgerald rated Buy SUCAMPO PHARMACEUTICALS INC (NASDAQ: SCMP) on 04/23/2013. Previously Cantor Fitzgerald rated Buy SUCAMPO PHARMACEUTICALS INC (NASDAQ: SCMP) on
04/03/2013., when the stock price was $6.70. Since then, SUCAMPO PHARMACEUTICALS INC has gained 316.72% as of 01/22/2016's recent price of $27.92.
If you would have followed the previous Cantor Fitzgerald's recommendation on SCMP, you would have gained 316.71% of your investment in 1024 days.

Sucampo Pharmaceuticals, Inc. is an emerging pharmaceutical company focused on the discovery, development and commercialization of proprietary drugs based on prostones, a class of compounds derived from functional fatty acids that occur naturally in the human body. Sucampo is focused on developing prostones for the treatment of gastrointestinal, respiratory, vascular and central nervous system diseases and disorders.

Cantor U.S. Equity Research provides timely and insightful opinions on select stocks. We look at key drivers of the stock price, including company and industry fundamentals, capital markets influences and overall economic trends to provide critical and in-depth analysis. Our focus is on small and mid-cap companies in the following sectors: * Marine Transportation * Life Sciences * Clean Technology & Energy Efficiency * Real Estate * Communications Technology * Internet * Enterprise Software
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
4/23/2013 2:25 PM Buy
None
7.93 10.00
as of 12/13/2013
1 Week up  5.75 %
1 Month up  18.58 %
3 Months up  35.67 %
1 YTD down  -2.64 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
4/3/2013 8:25 AM Buy
None
6.70 9.00

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy